Novel Developments in Stem Cell Mobilization

1. Front Matter

   Pages i-xiv

   PDF

2. Basic Science and Experimental Studies on Stem Cell Mobilization

   1. Front Matter

      Pages 1-1

      PDF

   2. Preclinical Experience with AMD3100 for Mobilization of Hematopoietic Stem and Progenitor Cells

      • Hal E. Broxmeyer

      Pages 3-22

   3. Molecular Pharmacology of CXCR4 Inhibition

      • Anne Steen, Mette Marie Rosenkilde

      Pages 23-35

   4. Combination Strategies for Stem Cell Mobilization Targeting CXCR4 and S1P Receptors

      • Nadia Harun, Kenneth Bradstock, Linda J. Bendall

      Pages 37-54

   5. Should We Stay or Should We Go Now?

      • Eike C. Buss, Anthony D. Ho

      Pages 55-69

   6. Role of the CXCR4/CXCL12 Axis in Hematopoietic Stem Cell Trafficking

      • Amnon Peled, Arnon Nagler

      Pages 71-85

3. Clinical Studies on Stem Cell Mobilization

   1. Front Matter

      Pages 87-87

      PDF

4. Clinical Studies on Stem Cell Mobilization

   1. Early Studies of AMD3100/Plerixafor in Healthy Volunteers

      • David C. Dale, W. Conrad Liles

      Pages 89-101

   2. The Current Role of Plerixafor in Stem Cell Mobilization for Hematopoietic Stem Cell Transplantation

      • Amy R. MacKenzie, Matias E. Valsecchi, Neal Flomenberg

      Pages 103-131

   3. Experience with Apheresis Procedures After Plerixafor Mobilisation

      • Kenneth Douglas

      Pages 133-163

   4. Influence of Different Stem Cell Mobilization Strategies on Graft Composition and Outcome of Autologous or Allogeneic Transplantation

      • Stefan Fruehauf, Guido Tricot

      Pages 165-200

   5. Relevance and Clinical Implications of Tumor Cell Mobilization in Autologous Transplantation of Multiple Myeloma and Non-Hodgkin’s Lymphoma

      • Stefan Fruehauf, Anthony D. Ho, Jessie Hanrahan, Frank J. Hsu, John F. DiPersio

      Pages 201-219

   6. Plerixafor: Data from the Compassionate Use Program

      • Maximilian M. Fresen, Kai Hübel

      Pages 221-234

   7. Stem Cell Mobilization with Chemomobilization Plus Plerixafor in Hard-to-Mobilize Patients: The Experience at Kuopio University Hospital, Finland

      • Esa Jantunen, Tapio Nousiainen

      Pages 235-246

   8. Blood Stem Cell Mobilization in Solid Tumors: Experience with Plerixafor and Alternative Ways of Hematopoietic Stem Cell Mobilization

      • Guido Kobbe, Rainer Haas

      Pages 247-262

   9. Mobilization with Chemotherapy + G-CSF + Plerixafor in Europe: The Italian Experience

      • Roberto M. Lemoli, Alessandra D’ Addio

      Pages 263-276

   10. Experience with Plerixafor in Poor Mobilizers

       • Catherine H. Roberts, John M. McCarty

       Pages 277-301

   11. CXCR4 Antagonists

       • Klaus Dembowsky, Barbara Romagnoli, Johann Zimmermann, Eric Chevalier, Christian Ludin, Daniel Obrecht

       Pages 303-332

5. CXCR4 Antagonists for Treatment of Leukemias and Solid Tumors

   1. Front Matter

      Pages 333-333

      PDF

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

• CXCR4
• Cancer Research
• Mobilization
• Plerixafor
• Stem Cell

• , Zentrum für Tumordiagnostik und –therapi, Paracelsus-Klinik, Osnabrück, Germany

  Stefan Fruehauf

• Deutsches Krebsforschungszentrum (G360), Heidelberg, Germany

  W. Jens Zeller

• Private, Cresco, USA

  Gary Calandra

Policies and ethics